EXTON, Pa., Aug. 30 /PRNewswire-FirstCall/ -- ViroPharma Incorporated today announced that Vincent Milano, vice-president, chief operating officer and chief financial officer of ViroPharma, will present at the Thomas Weisel Partners 2007 Healthcare Conference at 8:00 A.M. ET on Wednesday, September 5, 2007. The conference is being held at the Four Seasons Hotel in Boston, MA.
Mr. Milano will also present at the 14th Annual BioCentury Newsmakers in the Biotech Industry Conference at 1:30 P.M. ET on Thursday, September 6, 2007. The conference is being held at the Millennium Broadway Hotel in New York.
ViroPharma also announced that Michel de Rosen, president and chief executive officer of ViroPharma, will present at the Bear Stearns 20th Annual Healthcare Conference at 3:30 P.M. ET on Monday, September 10, 2007. The conference is being held at the Grand Hyatt in New York.
ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conference.
About ViroPharma Incorporated
ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/docs/Vancocin_pi_2007.htm). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the company's website at www.viropharma.com.
ViroPharma IncorporatedCONTACT: William C. Roberts, Director, Corporate Communications,+1-610-321-6288, or Robert A. Doody, Manager, Corporate Communications,+1-610-321-6290, both of ViroPharma Incorporated
